Pacific Biosciences of California Secures Order For Five Additional Instruments

Pacific Biosciences of California shares gained almost 4% pre-market after the genetic sequencing systems developer said GrandOmics Biosciences of Beijing has agreed to purchase five additional Sequel instruments.

The instruments will support China’s precision medicine initiative, the company said, with a specific focus on providing the genetic diagnosis of inherited diseases.

GrandOmics will acquire the systems through its subsidiary NextOmics in Wuhan, Pacific Biosciences said. The company was one of the early commercial sequencing service providers in China to purchase a Sequel System, Pacific Biosciences said.

Leave a Comment